Your browser doesn't support javascript.
loading
Including the patient voice in the development and implementation of patient-reported outcomes in cancer clinical trials.
Addario, Bonnie; Geissler, Jan; Horn, Marcia K; Krebs, Linda U; Maskens, Deborah; Oliver, Kathy; Plate, Ananda; Schwartz, Erin; Willmarth, Nicole.
Afiliação
  • Addario B; GO2 Foundation for Lung Cancer, San Carlos, CA, Washington DC, USA.
  • Geissler J; Patvocates, Riemerling, Germany.
  • Horn MK; ICAN, International Cancer Advocacy Network, Phoenix, AZ, USA.
  • Krebs LU; International Society of Nurses in Cancer Care, Vancouver, BC, Canada.
  • Maskens D; International Kidney Cancer Coalition, Guelph, ON, Canada.
  • Oliver K; International Brain Tumour Alliance, Tadworth, UK.
  • Plate A; Myeloma Patients Europe, Brussels, Belgium.
  • Schwartz E; The Max Foundation, Seattle, WA, USA.
  • Willmarth N; American Brain Tumor Association, Chicago, IL, USA.
Health Expect ; 23(1): 41-51, 2020 02.
Article em En | MEDLINE | ID: mdl-31722131
ABSTRACT
CONTEXT Patient-reported outcomes (PROs) are used in parallel with clinical evidence to inform decisions made by industry, clinicians, regulators, health technology assessment bodies and other health-care decision-makers. In addition, PRO data can also guide shared decision making and individual patient choice. Yet, the quality of many PROs in cancer clinical trials is suboptimal and requires improvement to add value to health care and policy decision making.

OBJECTIVE:

To show how the integration of the patient and/or patient advocate at all stages of PRO development can help to realize the full potential of PROs.

METHODS:

We examined the literature to show that the patient voice is often absent from the planning and implementation of PROs in cancer clinical trials. Good practice examples from the literature were combined with guideline recommendations, training or educational resources, and our own experience to create detailed practical steps for the inclusion of patients and/or patient advocates throughout PRO development.

RESULTS:

Patient or patient advocates can play an active role in shaping PROs that are meaningful to the patient. They can contribute to content, choice of medium and implementation in a way that may support PRO completion and minimize missing data. Patients and their advocates can work to ensure PRO findings are disseminated appropriately in a way that is accessible to patients.

CONCLUSION:

This practical guidance aims to optimize PRO development and implementation in clinical trials, resulting in robust, relevant data that reflect the patient experience and that support decisions made by all stakeholders involved in research and health care.
Assuntos
Palavras-chave

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Defesa do Paciente / Participação do Paciente / Projetos de Pesquisa / Ensaios Clínicos como Assunto / Medidas de Resultados Relatados pelo Paciente / Neoplasias Tipo de estudo: Guideline / Health_technology_assessment / Prognostic_studies Limite: Humans Idioma: En Revista: Health Expect Assunto da revista: PESQUISA EM SERVICOS DE SAUDE / SAUDE PUBLICA Ano de publicação: 2020 Tipo de documento: Article País de afiliação: Estados Unidos

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Defesa do Paciente / Participação do Paciente / Projetos de Pesquisa / Ensaios Clínicos como Assunto / Medidas de Resultados Relatados pelo Paciente / Neoplasias Tipo de estudo: Guideline / Health_technology_assessment / Prognostic_studies Limite: Humans Idioma: En Revista: Health Expect Assunto da revista: PESQUISA EM SERVICOS DE SAUDE / SAUDE PUBLICA Ano de publicação: 2020 Tipo de documento: Article País de afiliação: Estados Unidos